Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015.

Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill. 2015;20(5) Authors: McNeil S, Andrew M, Ye L, Haguinet F, Hatchette T, ElSherif M, LeBlanc J, Ambrose A, McGeer A, McElhaney J, Loeb M, MacKinnon-Cameron D, Sharma R, Dos Santos G, Shinde V, Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN) PMID: 25677052 [PubMed - in process]
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research

Related Links:

(CNN) — The US Centers for Disease Control and Prevention told doctors on a conference call this week that the United States is seeing more flu than is typical for this time of year. “Influenza is off to an early start,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was on the CDC call, which included members of the Influenza Hospitalization Surveillance Network, a group of hospitals that help the CDC assess the severity of the flu season. Thirty states are seeing flu activity — for this time of year, that’s the most states in a decade. Three s...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Seen On WBZ-TV Syndicated CBSN Boston flu season Source Type: news
Condition:   Influenza Intervention:   Drug: Flumist Quadrivalent Nasal Product Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: QIV was immunogenic against the additional B lineage strain (B Victoria) without significantly compromising the immunogenicity of the other three vaccine strains, therefore, adding a second B lineage strain in QIV could broaden protection against influenza B infection in this age group. As the QIV immunogenicity differed regarding the four antigens, formulation adjustments to increase the antigen concentration of the serotypes that have lower immunogenicity could increase effectiveness. Prior season vaccination was associated with lower antibody response to a new vaccine, although not consistent through the vaccine strains.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Conditions:   Flu, Human;   Influenza, Human Intervention:   Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination Sponsors:   Harvard University;   Stanford University;   Massachusetts Institute of Technology Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines. Int Rev Immunol. 2019 Nov 09;:1-16 Authors: Biswas A, Chakrabarti AK, Dutta S Abstract Annual flu led by influenza viruses is contemplated to be one of the foremost global health challenges due to its rapid spread leading to the life-threatening epidemic or pandemic. An enormous number of people die due to flu and its associated intricacies every year. Annual vaccination is considered to be the gold standard strategy to protect the individual from acquiring infection and further de...
Source: International Reviews of Immunology - Category: Allergy & Immunology Tags: Int Rev Immunol Source Type: research
A recent study in this journal reported the cross-species transmission of a novel swine H3N2 influenza A virus (IAV) to humans and suggested a heavy threat from the H3N2 IAVs (1). Vaccination remains the primary option for the control of influenza, but the protective efficiency of seasonal vaccines against H3N2 IAVs are suboptimal. Recent human H3N2 IAVs have shown poor growth in MDCK cells and eggs due to their low receptor binding affinities. A high yield strain is required for the vaccine manufacture, however, mutations of vaccine seeds during egg adaptation has reported to reduce the vaccine effectiveness (2).
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research
Current influenza vaccines manufactured using eggs have considerable limitations, both in terms of scale up production and the potential impact passaging through eggs can have on the antigenicity of the vaccine virus strains. Alternative methods of manufacture are required, particularly in the context of an emerging pandemic strain. Here we explore the production of recombinant influenza haemagglutinin using the ciliated protozoan Tetrahymena thermophila. For the first time we were able to produce haemagglutinin from both seasonal influenza A and B strains. This ciliate derived material was immunogenic, inducing an antibod...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Infectious Diseases | Influenza | Influenza Vaccine | Laboratory Medicine | Vaccines